Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev-Reference-Cited by-同舟云学术

Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev

Published:2019-10 Issue: Volume:30 Page:v894-v895
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Ray-Coquard I.L.,Pautier P.,Pignata S.,Pérol D.,González-Martín A.,Sevelda P.,Fujiwara K.,Vergote I.B.,Colombo N.,Mäenpää J.,Selle F.,Sehouli J.,Lorusso D.,Alia E M Guerra,Lefeuvre-Plesse C.,Canzler U.,Lortholary A.,Marmé F.,Pujade-Lauraine E.,Harter P.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz394.053/30083423/mdz394.053.pdf

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities;Cancers;2023-01-10

2. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours;European Journal of Medicinal Chemistry;2022-11

3. Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers;Current Oncology Reports;2022-03-26

4. Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer;Cancers;2022-03-02

5. Targeting DNA damage repair pathways in pancreas cancer;Cancer and Metastasis Reviews;2021-08-17